These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24295981)

  • 1. An NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system.
    Duncan MC; Wong WR; Dupzyk AJ; Bray WM; Linington RG; Auerbuch V
    Antimicrob Agents Chemother; 2014; 58(2):1118-26. PubMed ID: 24295981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piericidin A1 Blocks
    Morgan JM; Duncan MC; Johnson KS; Diepold A; Lam H; Dupzyk AJ; Martin LR; Wong WR; Armitage JP; Linington RG; Auerbuch V
    mSphere; 2017; 2(1):. PubMed ID: 28217742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic
    Morgan JM; Lam HN; Delgado J; Luu J; Mohammadi S; Isberg RR; Wang H; Auerbuch V
    Front Cell Infect Microbiol; 2018; 8():404. PubMed ID: 30524970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.
    Lam H; Schwochert J; Lao Y; Lau T; Lloyd C; Luu J; Kooner O; Morgan J; Lokey S; Auerbuch V
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of mammalian proteins that collaborate with type III secretion system function: involvement of a chemokine receptor in supporting translocon activity.
    Sheahan KL; Isberg RR
    mBio; 2015 Feb; 6(1):e02023-14. PubMed ID: 25691588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis.
    Harmon DE; Davis AJ; Castillo C; Mecsas J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3241-54. PubMed ID: 20498321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IscR is essential for yersinia pseudotuberculosis type III secretion and virulence.
    Miller HK; Kwuan L; Schwiesow L; Bernick DL; Mettert E; Ramirez HA; Ragle JM; Chan PP; Kiley PJ; Lowe TM; Auerbuch V
    PLoS Pathog; 2014 Jun; 10(6):e1004194. PubMed ID: 24945271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of host membrane pore formation by the Yersinia pseudotuberculosis type III secretion system on the macrophage innate immune response.
    Kwuan L; Adams W; Auerbuch V
    Infect Immun; 2013 Mar; 81(3):905-14. PubMed ID: 23297383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immune recognition of Yersinia pseudotuberculosis type III secretion.
    Auerbuch V; Golenbock DT; Isberg RR
    PLoS Pathog; 2009 Dec; 5(12):e1000686. PubMed ID: 19997504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A type III secretion system inhibitor targets YopD while revealing differential regulation of secretion in calcium-blind mutants of Yersinia pestis.
    Jessen DL; Bradley DS; Nilles ML
    Antimicrob Agents Chemother; 2014; 58(2):839-50. PubMed ID: 24247143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa.
    Zetterström CE; Hasselgren J; Salin O; Davis RA; Quinn RJ; Sundin C; Elofsson M
    PLoS One; 2013; 8(12):e81969. PubMed ID: 24324737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yersinia pseudotuberculosis YopD mutants that genetically separate effector protein translocation from host membrane disruption.
    Adams W; Morgan J; Kwuan L; Auerbuch V
    Mol Microbiol; 2015 May; 96(4):764-78. PubMed ID: 25684661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron availability and oxygen tension regulate the Yersinia Ysc type III secretion system to enable disseminated infection.
    Hooker-Romero D; Mettert E; Schwiesow L; Balderas D; Alvarez PA; Kicin A; Gonzalez AL; Plano GV; Kiley PJ; Auerbuch V
    PLoS Pathog; 2019 Dec; 15(12):e1008001. PubMed ID: 31869388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translocation of surface-localized effectors in type III secretion.
    Akopyan K; Edgren T; Wang-Edgren H; Rosqvist R; Fahlgren A; Wolf-Watz H; Fallman M
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1639-44. PubMed ID: 21220342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammasome activation in response to the Yersinia type III secretion system requires hyperinjection of translocon proteins YopB and YopD.
    Zwack EE; Snyder AG; Wynosky-Dolfi MA; Ruthel G; Philip NH; Marketon MM; Francis MS; Bliska JB; Brodsky IE
    mBio; 2015 Feb; 6(1):e02095-14. PubMed ID: 25691590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Yersinia effector with enhanced inhibitory activity on the NF-κB pathway activates the NLRP3/ASC/caspase-1 inflammasome in macrophages.
    Zheng Y; Lilo S; Brodsky IE; Zhang Y; Medzhitov R; Marcu KB; Bliska JB
    PLoS Pathog; 2011 Apr; 7(4):e1002026. PubMed ID: 21533069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial internalization is required to trigger NIK-dependent NF-κB activation in response to the bacterial type three secretion system.
    Duncan MC; Herrera NG; Johnson KS; Engel JN; Auerbuch V
    PLoS One; 2017; 12(2):e0171406. PubMed ID: 28166267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying Yersinia pseudotuberculosis Type III Secretion System Activity Following Iron Starvation and Anaerobic Growth.
    Ohanyan M; Hooker-Romero D; Balderas D; Auerbuch V
    J Vis Exp; 2024 May; (207):. PubMed ID: 38884494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the Physical and Bioactive Properties of Bromo- and Iodo-Containing Sponge-Derived Compounds Possessing an Oxyphenylethanamine Core.
    McCauley EP; Lam H; Lorig-Roach N; Luu J; Lloyd C; Tenney K; Pietraszkiewicz H; Diaz C; Valeriote FA; Auerbuch V; Crews P
    J Nat Prod; 2017 Dec; 80(12):3255-3266. PubMed ID: 29144750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.
    Kauppi AM; Nordfelth R; Uvell H; Wolf-Watz H; Elofsson M
    Chem Biol; 2003 Mar; 10(3):241-9. PubMed ID: 12670538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.